Arcutis Biotherapeutics Inc
ARQT14.280USD
-0.010-0.07%
交易中 （美東）報價延遲15分鐘
1.70B總市值
虧損本益比TTM
關於 Arcutis Biotherapeutics Inc 公司
Arcutis Biotherapeutics, Inc. 是一家商業階段的醫學皮膚病學公司。該公司專注於開發和商業化具有高度未滿足醫療需求的皮膚病治療方法。其產品組合包括局部和全身治療，具有治療免疫介導的皮膚病和病症的潛力。其主打產品 ZORYVE 用於治療 12 歲或以上人羣的斑塊狀銀屑病，包括間擦區域的銀屑病。ZORYVE 乳膏是羅氟司特的每日一次局部製劑，羅氟司特是一種強效且選擇性的磷酸二酯酶 4 (PDE4) 抑制劑。該公司的產品線包括 ARQ-255、ARQ-252 和 ARQ-234。ARQ-255 是爲斑禿開發的。ARQ-252 是伊伐替尼的替代局部乳膏製劑，該公司正在開發用於治療慢性手部溼疹和白癜風。 ARQ-255 是爲治療斑禿而開發的。
公司簡介
公司代碼ARQT
公司名稱Arcutis Biotherapeutics Inc
上市日期Jan 31, 2020
CEOMr. Todd Franklin Watanabe
員工數量342
證券類型Ordinary Share
年結日Jan 31
公司地址3027 Townsgate Road
城市WESTLAKE VILLAGE
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編91361
電話18054185006
網址https://arcutis.com/
公司代碼ARQT
上市日期Jan 31, 2020
CEOMr. Todd Franklin Watanabe
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Bhaskar Chaudhuri, Ph.D.
Dr. Bhaskar Chaudhuri, Ph.D.
Independent Director
Independent Director
917.81K
+0.84%
Mr. Todd Franklin Watanabe
Mr. Todd Franklin Watanabe
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
721.32K
-0.28%
Dr. Howard G. Welgus, M.D.
Dr. Howard G. Welgus, M.D.
Independent Director
Independent Director
100.21K
-8.42%
Mr. Masaru (Mas) Matsuda, Esq., J.D.
Mr. Masaru (Mas) Matsuda, Esq., J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
78.26K
-8.03%
Ms. Latha Vairavan
Ms. Latha Vairavan
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
65.10K
--
Ms. Sue-Jean Lin
Ms. Sue-Jean Lin
Independent Director
Independent Director
26.73K
+39.78%
Mr. Patrick J. Heron
Mr. Patrick J. Heron
Independent Chairman of the Board
Independent Chairman of the Board
26.43K
+40.42%
Ms. Neha Krishnamohan
Ms. Neha Krishnamohan
Independent Director
Independent Director
23.36K
+48.32%
Ms. Terrie J. Curran
Ms. Terrie J. Curran
Independent Director
Independent Director
--
--
Ms. Halley E. Gilbert, J.D.
Ms. Halley E. Gilbert, J.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Bhaskar Chaudhuri, Ph.D.
Dr. Bhaskar Chaudhuri, Ph.D.
Independent Director
Independent Director
917.81K
+0.84%
Mr. Todd Franklin Watanabe
Mr. Todd Franklin Watanabe
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
721.32K
-0.28%
Dr. Howard G. Welgus, M.D.
Dr. Howard G. Welgus, M.D.
Independent Director
Independent Director
100.21K
-8.42%
Mr. Masaru (Mas) Matsuda, Esq., J.D.
Mr. Masaru (Mas) Matsuda, Esq., J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
78.26K
-8.03%
Ms. Latha Vairavan
Ms. Latha Vairavan
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
65.10K
--
Ms. Sue-Jean Lin
Ms. Sue-Jean Lin
Independent Director
Independent Director
26.73K
+39.78%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Suvretta Capital Management, LLC
9.58%
Jennison Associates LLC
9.32%
Rubric Capital Management LP
9.20%
Frazier Life Sciences Management, L.P.
7.37%
BlackRock Institutional Trust Company, N.A.
6.63%
Other
57.89%
持股股東
持股股東
佔比
Suvretta Capital Management, LLC
9.58%
Jennison Associates LLC
9.32%
Rubric Capital Management LP
9.20%
Frazier Life Sciences Management, L.P.
7.37%
BlackRock Institutional Trust Company, N.A.
6.63%
Other
57.89%
股東類型
持股股東
佔比
Investment Advisor
32.24%
Investment Advisor/Hedge Fund
31.96%
Hedge Fund
29.96%
Private Equity
7.39%
Research Firm
4.30%
Individual Investor
2.19%
Venture Capital
1.84%
Sovereign Wealth Fund
0.45%
Bank and Trust
0.42%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
477
132.39M
111.07%
-21.95M
2025Q1
487
132.87M
111.51%
-24.00M
2024Q4
453
136.04M
114.96%
-23.73M
2024Q3
433
136.12M
116.66%
-19.10M
2024Q2
416
134.94M
116.78%
-20.37M
2024Q1
392
131.83M
115.81%
+2.26M
2023Q4
366
104.30M
108.66%
+5.22M
2023Q3
364
79.57M
131.78%
-15.32M
2023Q2
359
84.02M
139.44%
-6.66M
2023Q1
352
83.59M
140.11%
+3.40M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Suvretta Capital Management, LLC
11.42M
9.58%
+23.84K
+0.21%
Mar 31, 2025
Jennison Associates LLC
11.36M
9.53%
-978.92K
-7.93%
Mar 31, 2025
Rubric Capital Management LP
10.97M
9.2%
--
--
Mar 31, 2025
Frazier Life Sciences Management, L.P.
8.79M
7.37%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
7.91M
6.63%
-197.41K
-2.44%
Mar 31, 2025
The Vanguard Group, Inc.
6.79M
5.7%
+373.66K
+5.82%
Mar 31, 2025
Polar Capital LLP
6.71M
5.63%
-670.91K
-9.09%
Mar 31, 2025
State Street Global Advisors (US)
4.47M
3.75%
-476.52K
-9.63%
Mar 31, 2025
Gilder Gagnon Howe & Co. LLC
4.10M
3.44%
+193.06K
+4.95%
Mar 31, 2025
Morgan Stanley & Co. LLC
3.08M
2.58%
-403.45K
-11.59%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Simplify Health Care ETF
4.4%
Virtus LifeSci Biotech Clinical Trials ETF
0.93%
SPDR S&P Biotech ETF
0.55%
First Trust Small Cap Growth AlphaDEX Fund
0.49%
Direxion Daily S&P Biotech Bull 3X Shares
0.31%
Federated Hermes MDT Small Cap Core ETF
0.28%
First Trust Small Cap Core Alphadex Fund
0.27%
ProShares Ultra Nasdaq Biotechnology
0.19%
Invesco Nasdaq Biotechnology ETF
0.19%
Inspire Small/Mid Cap ESG ETF
0.17%
查看更多
Simplify Health Care ETF
佔比4.4%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.93%
SPDR S&P Biotech ETF
佔比0.55%
First Trust Small Cap Growth AlphaDEX Fund
佔比0.49%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.31%
Federated Hermes MDT Small Cap Core ETF
佔比0.28%
First Trust Small Cap Core Alphadex Fund
佔比0.27%
ProShares Ultra Nasdaq Biotechnology
佔比0.19%
Invesco Nasdaq Biotechnology ETF
佔比0.19%
Inspire Small/Mid Cap ESG ETF
佔比0.17%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
